Docoh
Loading...

25 results

Filter options loading...
Top filers
Top filing types
Recent filing years
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
; operating margin; profit margin; sales performance; sales quota attainment; new sales; cross/integrated sales; customer engagement; internal revenue … pre-approval of the engagement of the Company’s independent auditor to perform audit as well as permissible non-audit services for the Company
10-K/A
2020 FY
PCSA Processa Pharmaceuticals Inc
7 Apr 21
Annual report (amended)
4:23pm
describes the Audit Committee’s policies and procedures regarding pre-approval of the engagement of the Company’s independent auditor to perform audit … with an engagement letter during the March-May quarter of each year outlining the scope of the audit services proposed to be performed in connection
8-K
PCSA Processa Pharmaceuticals Inc
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
conditions. The Company engaged Tribal Capital Markets, LLC (“Tribal”) as placement agent for the Offering pursuant to an engagement letter agreement
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
13 Oct 20
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
9:30am
and safely attack high-value milestones. Elion sought out a collaborative engagement with the very best development partners and we found that partner
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
oral agreements, understandings and negotiations with respect to the subject matter hereof, including the engagement letter dated July 24, 2020
S-1/A
EX-1.1
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
and negotiations with respect to the subject matter hereof, including the engagement letter dated July 24, 2020, by and between the Company and Craig-Hallum
S-1/A
EX-3.2
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
or engagement or to pledge its credit or to render it liable for any purpose or for any amount. Section 35. Voting Of Securities Owned By The Corporation. All
S-1/A
EX-10.5
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
; customer satisfaction; operating margin; profit margin; sales performance; sales quota attainment; new sales; cross/integrated sales; customer engagement
DEF 14A
PCSA Processa Pharmaceuticals Inc
26 Apr 19
Definitive proxy
5:02pm
sales; cross/integrated sales; customer engagement; internal revenue growth; client retention; the achievement of research, production, or regulatory … ; sales performance; sales quota attainment; new sales; cross/integrated sales; customer engagement; internal revenue growth; client retention
10-K/A
2018 FY
PCSA Processa Pharmaceuticals Inc
5 Apr 19
Annual report (amended)
9:40pm
by reference to exhibit 10.5 to Form 10-K/A filed on April 17, 2018) Boustead Engagement Letter (incorporated by reference to exhibit 10.1 to Form 10-Q filed
10-K
2018 FY
PCSA Processa Pharmaceuticals Inc
28 Mar 19
Annual report
5:25pm
by reference to exhibit 10.5 to Form 10-K/A filed on April 17, 2018) Boustead Engagement Letter (incorporated by reference to exhibit 10.1 to Form 10-Q
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Oct 18
IPO registration (amended)
4:19pm
to Form 10-K/A filed on April 17, 2018) Boustead Engagement Letter (incorporated by reference to exhibit 10.1 to Form 10-Q filed on April 17, 2018
S-1/A
PCSA Processa Pharmaceuticals Inc
9 Oct 18
IPO registration (amended)
5:32pm
/A filed on April 17, 2018) Convertible Note (incorporated by reference to exhibit 10.5 to Form 10-K/A filed on April 17, 2018) Boustead Engagement
S-1/A
PCSA Processa Pharmaceuticals Inc
13 Sep 18
IPO registration (amended)
8:00pm
) Convertible Note (incorporated by reference to exhibit 10.5 to Form 10-K/A filed on April 17, 2018) Boustead Engagement Letter (incorporated
S-1
PCSA Processa Pharmaceuticals Inc
29 Jul 18
IPO registration
8:00pm
, 2018) Boustead Engagement Letter (incorporated by reference to exhibit 10.1 to Form 10-Q filed on April 17, 2018) Form of Purchase Agreement
10-Q
2018 Q1
PCSA Processa Pharmaceuticals Inc
21 May 18
Quarterly report
12:42pm
Engagement Letter Form of Purchase Agreement Form of Warrant Rule 153-14(a) Certification by Principal Executive Officer Section 1350 Certification
10-K/A
2017 FY
PCSA Processa Pharmaceuticals Inc
16 Apr 18
Annual report (amended)
8:00pm
of the Securities Exchange Act of 1934, as amended. On October 31, 2017 (the “Engagement Date”), the Company engaged BD & Company, Inc. (“BD”), as its new … independent registered public accounting firm. The engagement of BD was approved by the Company’s Board of Directors on October 31, 2017. During the years ended
10-K
2017 FY
PCSA Processa Pharmaceuticals Inc
15 Apr 18
Annual report
8:00pm
, as amended. On October 31, 2017 (the “Engagement Date”), the Company engaged BD & Company, Inc. (“BD”), as its new independent registered public … accounting firm. The engagement of BD was approved by the Company’s Board of Directors on October 31, 2017. During the years ended December 31, 2016
8-K/A
EX-99.3
PCSA Processa Pharmaceuticals Inc
23 Jan 18
Financial Statements and Exhibits
7:00pm
not been subjected to an audit or review or compilation engagement, and no assurance is provided on them. PROCESSA PHARMACEUTICALS, INC. UNAUDITED … statements have not been subjected to an audit or review or compilation engagement, and no assurance is provided on them. PROCESSA PHARMACEUTICALS
8-K
PCSA Processa Pharmaceuticals Inc
1 Nov 17
Changes in Registrant's Certifying Accountant
8:00pm
of such letter is filed as Exhibit 16.1 to this Form 8-K. On October 31, 2017 (the “Engagement Date”), the Company engaged BD & Co. (“BD”), as its new … independent registered public accounting firm. The engagement of BD was approved by the Company’s Board of Directors on October 31, 2017. During